Publication:
Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome

Simple item page
dc.contributor.authorSezgin, Canfeza
dc.contributor.authorÖzdemir, Necmettin
dc.contributor.authorGöker, Erdem
dc.contributor.buuauthorKurt, Ender
dc.contributor.buuauthorEvrensel, Türkkan
dc.contributor.buuauthorManavoğlu, Osman
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentİç Hastalıkları Ana Bilim Dalı
dc.contributor.orcid0000-0002-9732-5340
dc.contributor.researcheridAAJ-1027-2021
dc.contributor.scopusid7006207332
dc.contributor.scopusid6603942124
dc.contributor.scopusid6602587152
dc.date.accessioned2022-10-25T06:04:05Z
dc.date.available2022-10-25T06:04:05Z
dc.date.issued2007-01
dc.description.abstractObjective: Capecitabine exerts considerable therapeutic efficacy in metastatic breast cancer (MBC) patients previously treated with anthracyclines and taxanes. Materials and Methods: In this study, the efficacy and safety of lower dose capecitabine (2000 Mg/m(2)/d) in patients with anthra-cycline- and taxane-pretreated MBC were studied with a special emphasis on the potential predictors of time to tumor progression (TTP) and response to the capecitabine treatment. Results: The overall response rate (ORR) was 17%. The median TTP was 5 months. Among various factors analyzed, univariate analysis showed that a performance status (PS) of 2 and the presence of visceral metastases were inversely correlated with TTP. Multivariate analysis showed that a poor PS score was associated with impaired TTP. Conclusions: Our study indicates that lower dose capecitabine has substantial antitumor activity and a favorable safety profile in the treatment of anthracycline- and taxane-pretreated MBC. Also, only performance score was demonstrated to be a significant parameter affecting TTP.
dc.identifier.citationSezgin, C. vd. (2007). "Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome". Southern Medical Journal, 100(1), 27-32.
dc.identifier.endpage32
dc.identifier.issn0038-4348
dc.identifier.issn1541-8243
dc.identifier.issue1
dc.identifier.pubmed17269522
dc.identifier.scopus2-s2.0-33846247078
dc.identifier.startpage27
dc.identifier.urihttps://doi.org/10.1097/01.smj.0000252968.87824.19
dc.identifier.urihttps://sma.org/southern-medical-journal/article/efficacy-of-lower-dose-capecitabine-in-patients-with-metastatic-breast-cancer-and-factors-influencing-therapeutic-response-and-outcome/
dc.identifier.urihttp://hdl.handle.net/11452/29196
dc.identifier.volume100
dc.identifier.wos000246777300009
dc.indexed.scopusScopus
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.collaborationYurt içi
dc.relation.journalSouthern Medical Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectGeneral & internal medicine
dc.subjectCapecitabine
dc.subjectMetastatic breast cancer
dc.subjectMulticenter Phase II
dc.subjectCarcinoma
dc.subjectAmplification
dc.subjectSafety
dc.subject.emtreeTamoxifen
dc.subject.emtreeAnthracycline
dc.subject.emtreeCapecitabine
dc.subject.emtreeCyclophosphamide
dc.subject.emtreeFluorouracil
dc.subject.emtreeMethotrexate
dc.subject.emtreeConjunctivitis
dc.subject.emtreeTaxane derivative
dc.subject.emtreeAdult
dc.subject.emtreeAged
dc.subject.emtreeAnemia
dc.subject.emtreeAnorexia
dc.subject.emtreeAntineoplastic activity
dc.subject.emtreeArticle
dc.subject.emtreeBreast cancer
dc.subject.emtreeCancer chemotherapy
dc.subject.emtreeHuman
dc.subject.emtreeDiarrhea
dc.subject.emtreeDrug efficacy
dc.subject.emtreeDrug response
dc.subject.emtreeDrug safety
dc.subject.emtreeDyspepsia
dc.subject.emtreeFatigue
dc.subject.emtreeHand foot syndrome
dc.subject.emtreeNausea
dc.subject.emtreeMultivariate analysis
dc.subject.emtreeInfection
dc.subject.emtreeMajor clinical study
dc.subject.emtreeSide effect
dc.subject.emtreeToxic hepatitis
dc.subject.emtreeTreatment outcome
dc.subject.emtreeUnivariate analysis
dc.subject.meshDeoxycytidine
dc.subject.meshAdministration, oral
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntimetabolites, antineoplastic
dc.subject.meshBreast neoplasms
dc.subject.meshDisease progression
dc.subject.meshNeoplasm metastasis
dc.subject.meshFollow-up studies
dc.subject.meshRetrospective studies
dc.subject.meshDose-response relationship, drug
dc.subject.meshFemale
dc.subject.meshFluorouracil
dc.subject.meshHumans
dc.subject.meshMiddle aged
dc.subject.meshProdrugs
dc.subject.meshSurvival rate
dc.subject.meshTreatment outcome
dc.subject.scopusCapecitabine; Hand Foot Syndrome; Vinorelbine Tartrate
dc.subject.wosMedicine, general & internal
dc.titleEfficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome
dc.typeArticle
dc.wos.quartileQ3
dc.wos.quartileQ3
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/İç Hastalıkları Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi
local.indexed.atPubMed
local.indexed.atWOS
local.indexed.atScopus

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

İndeksli Yayınlar / Indexed Publications